BriaCell Therapeutics Corp.
BCTX
of the Company BriaCell Therapeutics Corp. ( Briacell or the Company ) is a clinical-stage biotechnology company that is developing novel immunotherapies to transform cancer care. Immunotherapies have come to the forefront in the fight against cancer as they harness the body's own immune system to recognize and destroy cancer cells.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$35M
▼ -32.7% YoY
Op. Margin
–
ROIC
-173.18%
▲ +74.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$29M
▼ -2.2% YoY
Op. Cash Flow (TTM)
-$29M
▼ -1.7% YoY
Net Debt
-$21M
Net Cash Position
Cash & Equiv.
$21M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with BCTX
BriaCell Therapeutics (BCTX) in two numbers
Questions about BriaCell Therapeutics
Does BriaCell Therapeutics (BCTX) pay a dividend?
No. BriaCell Therapeutics (BCTX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 28 Oct 2026 (period ending 31 Jul 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in BCTX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BCTX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.